Botanix Pharmaceuticals Limited (BXPHF) Discusses Quarterly Activity, Cash Flow, and Commercial Progress of Sofdra for Primary Axillary Hyperhidrosis Transcript

Jane Morgan

Good morning, everyone, and thank you for joining today’s investor webinar for Botanix Pharmaceuticals with the ASX ticket code BOT. My name is Jane Morgan, the Investor and Media Relations Manager. And today, I am joined by our Executive Chairman, Vincent Ippolito, our CEO, Dr. Howie McKibbon; and our U.S. CFO, Chris Lesovitz.

So for those who are new to the Botanix story, Botanix is a commercial stage dermatology company operating in Australia and the United States with this FDA-approved product Sofdra, which is available in America. Sofdra is a prescription-only topical gel medicine, which used to treat excessive underarm sweating or more formally known as primary axillary hyperhidrosis. It is used in treating adults and children aged 9 and over.

The company has transitioned from a development stage business into a revenue-generating commercial entity with Sofdra as its primary growth driver. Today’s presentation will be followed by a Q&A session. [Operator Instructions]

Vince, I’m going to hand to you.

Vincent Ippolito
MD & Executive Chairman

Thank you, Jane, and a pleasant good morning to everyone here joining us from Australia. Dr. Howie McKibbon and myself are here live in Sydney for this call. Chris Lesovitz is calling in from our headquarters in the U.S. and we’re pleased to present the Botanix Quarterly Activity Report and 4C Quarterly Cash Flow Report for the period ending 30 June 2026. And the company has come a long way since our highly successful commercial launch of Sofdra a little over a year ago, and we’re very pleased with